Analysis of Margin Index as a Method for Predicting Residual Disease After Breast-Conserving Surgery in a European Cancer Center.
Affiliation
Department of Surgery, Beaumont Hospital, Dublin 9, Ireland, jarlathbolger@yahoo.co.uk.Issue Date
2011-06-03
Metadata
Show full item recordCitation
Analysis of Margin Index as a Method for Predicting Residual Disease After Breast-Conserving Surgery in a European Cancer Center. 2011:notAnn Surg OncolJournal
Annals of surgical oncologyDOI
10.1245/s10434-011-1810-4PubMed ID
21638098Additional Links
http://www.ncbi.nlm.nih.gov/pubmed/21638098Abstract
INTRODUCTION: Breast-conserving surgery (BCS), followed by appropriate adjuvant therapies is established as a standard treatment option for women with early-stage invasive breast cancers. A number of factors have been shown to correlate with local and regional disease recurrence. Although margin status is a strong predictor of disease recurrence, consensus is yet to be established on the optimum margin necessary. Margenthaler et al. recently proposed the use of a "margin index," combining tumor size and margin status as a predictor of residual disease after BCS. We applied this new predictive tool to a population of patients with primary breast cancer who presented to a symptomatic breast unit to determine its suitability in predicting those who require reexcision surgery. METHODS: Retrospective analysis of our breast cancer database from January 1, 2000 to June 30, 2010 was performed, including all patients who underwent BCS. Of 531 patients who underwent BCS, 27.1% (144/531) required further reexcision procedures, and 55 were eligible for inclusion in the study. Margin index was calculated as: margin index = closest margin (mm)/tumor size (mm) × 100, with index >5 considered optimum. RESULTS: Of the 55 patients included, 31% (17/55) had residual disease. Fisher's exact test showed margin index not to be a significant predictor of residual disease on reexcision specimen (P = 0.57). Of note, a significantly higher proportion of our patients presented with T2/3 tumors (60% vs. 38%). CONCLUSIONS: Although an apparently elegant tool for predicting residual disease after BCS, we have shown that it is not applicable to a symptomatic breast unit in Ireland.Item Type
ArticleLanguage
enISSN
1534-4681ae974a485f413a2113503eed53cd6c53
10.1245/s10434-011-1810-4
Scopus Count
Collections
Related articles
- Margin index: a new method for prediction of residual disease after breast-conserving surgery.
- Authors: Margenthaler JA, Gao F, Klimberg VS
- Issue date: 2010 Oct
- Optimal use of re-excision in patients diagnosed with early-stage breast cancer by excisional biopsy treated with breast-conserving therapy.
- Authors: Caughran JL, Vicini FA, Kestin LL, Dekhne NS, Benitez PR, Goldstein NS
- Issue date: 2009 Nov
- Margin index is not a reliable tool for predicting residual disease after breast-conserving surgery for DCIS.
- Authors: Fisher CS, Klimberg VS, Khan S, Gao F, Margenthaler JA
- Issue date: 2011 Oct
- Role for intraoperative margin assessment in patients undergoing breast-conserving surgery.
- Authors: Cabioglu N, Hunt KK, Sahin AA, Kuerer HM, Babiera GV, Singletary SE, Whitman GJ, Ross MI, Ames FC, Feig BW, Buchholz TA, Meric-Bernstam F
- Issue date: 2007 Apr
- The role of margin status and reexcision in local recurrence following breast conservation surgery.
- Authors: Adams BJ, Zoon CK, Stevenson C, Chitnavis P, Wolfe L, Bear HD
- Issue date: 2013 Jul